Low-level viremia in nucleoside analog-treated chronic hepatitis B patients.
10.1097/CM9.0000000000001793
- Author:
Qian ZHANG
1
;
Da-Chuan CAI
1
;
Peng HU
1
;
Hong REN
1
Author Information
1. Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
- Publication Type:Review
- MeSH:
Antiviral Agents/therapeutic use*;
DNA, Viral;
Hepatitis B virus/genetics*;
Hepatitis B, Chronic/drug therapy*;
Humans;
Nucleosides/therapeutic use*;
Tenofovir/therapeutic use*;
Treatment Outcome;
Viremia/drug therapy*
- From:
Chinese Medical Journal
2021;134(23):2810-2817
- CountryChina
- Language:English
-
Abstract:
Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (<2000 IU/mL, detection limit of 10 IU/mL) after 48 weeks of antiviral treatment. Effective antiviral therapies for chronic hepatitis B (CHB) patients, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), have been shown to inhibit the replication of HBV DNA and prevent liver-related complications. However, even with long-term antiviral therapy, there are still a number of patients with persistent or intermittent LLV. At present, the research on LLV to address whether adversely affect the clinical outcome is limited, and the follow-up treatment for these patients is open to question. At the same time, the mechanism of LLV is not clear. In this review, we summarize the incidence of LLV, the association between LLV and long-term outcomes, possible mechanisms, and management strategies in these patient populations.
